AsiaTIDES: Oligonucleotide & Peptide Therapeutics is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr Jesper Lau - Vice President, Research Chemistry, Global Research Technologies, Novo Nordisk A/S, Denmark
After his Ph.D. in organic chemistry in 1990 at University of Southern Denmark and stay in the group of Professor Barry Trost at Standford University in California, he joined Health Care Discovery at Novo Nordisk.
Jesper Lau has 28 years’ experience in pharmaceutical discovery and holds a broad knowledge in small molecule based therapeutics as well as a comprehensive know-how within protein engineering especially within diabetes care with particular interest in glucagon like peptide 1 (GLP-1). He was project manager for once weekly GLP-1 and inventor of semaglutide.
In addition to project management Jesper Lau has been line manager since 1995 and was in 2008 appointed Vice President of the research unit today named Research Chemistry. He was promoted to adjunct professor at Fudan University in Shanghai 2016.